Trial Profile
A Modified Case Control Study to Identify Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Lapaquistat (Primary)
- Indications Hyperlipidaemia
- Focus Adverse reactions; Pharmacogenomic
- Sponsors Takeda
- 23 May 2012 Additional trial locations added as reported by ClinicalTrials.gov.
- 29 Jul 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
- 29 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.